Zogenix

Zogenix is an American pharmaceutical company headquartered in Emeryville, USA. He is engaged in the development and commercialization of drugs for the treatment of diseases of the central nervous system and orphan diseases. The main area of ​ ​ professional interest of the company is epilepsy and associated convulsive disorders.

History

2022: UCB bought Zogenix for $1.9 billion

On January 19, 2022, the Belgian pharmaceutical UCB announced the conclusion of an agreement to acquire Zogenix for $1.9 billion. The boards of directors of both companies approved the deal, it is planned to close in the second quarter of 2022.

Under the terms of the agreement, UCB will launch a tender offer to purchase all Zogenix shares placed at a price of $26 for each. A potential payment of another $2 per share will be added to the value if the Fintepla drug from Zogenix receives regulatory approval in Europe by the end of 2023.

UCB acquired Zogenix for $1.9 billion

Fintepla is a medicament for the treatment of Lennox-Gastaut syndrome. The drug is already approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for the treatment of attacks caused by Drave syndrome.

According to Stifel analyst Paul Matteis, the deal represents a favorable outcome for shareholders and attributes the good value of the drug. According to Matteis, Zogenix needed to increase Fintepla's market share in Drave drugs, antiepileptic drugs, and prove the role of the drug in Lennox-Gastout disease compared to other antiepileptic drugs approved to treat this disease. These tasks will now be assigned to UCB, which plans to accelerate patients' access to Fintepla.

According to Biopharmadive, the estimates of biotechnology companies fell significantly against the backdrop of an industry-wide decline since the end of 2021 and continued to decline in early 2022. With billions of dollars in cash available to top drugmakers, many observers expect a surge in acquisitions, especially as patents from some top sellers expire.^[1]

Notes